Trials / Completed
CompletedNCT03437382
Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study
HOlmium Radioembolization as Adjuvant Treatment to Radiofrequency Ablation for Early STage Hepatocellular Carcinoma (HORA EST HCC)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Leiden University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this multi-center, dose-finding study, patients with early stage hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer (BCLC) staging system will be included to receive percutaneous radiofrequency ablation in combination with RFA with adjuvant segmental radioembolization.
Detailed description
RFA + adjuvant radioembolsation with Quirem Spheres
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Quirem Medical Holmium-166 radioembolization microspheres | radioembolisation as adjuvant treatment to RFA |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2021-03-17
- Completion
- 2021-03-17
- First posted
- 2018-02-19
- Last updated
- 2021-03-18
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03437382. Inclusion in this directory is not an endorsement.